Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Rose Bengal-Based Drug Kills Both Primary and Secondary Melanoma Tumors

By BiotechDaily International staff writers
Posted on 02 Sep 2013
Drug developers have discovered the immunological mechanism that underlies the ability of the candidate drug PV-10 to induce regression of primary and secondary melanoma tumors.

PV-10, which was developed by Provectus Pharmaceuticals, Inc., (Knoxville, TN, USA) is a 10% solution of Rose Bengal formulated for IL (intralesional) injection. Rose Bengal is a water-soluble xanthene dye that had been previously employed in liver function studies and is still in use by ophthalmologists.

Investigators at the Moffitt Cancer Center (Tampa, FL, USA) worked with two different mouse models: BALB/c mice bearing MT-901 breast cancer and C57BL/6 mice that had been injected with B16 melanoma cells to establish one subcutaneous primary tumor and multiple secondary lung lesions.

Results published in the July 17, 2013, online edition of the journal PLOS ONE revealed that treatment of the subcutaneous lesion with a single injection of IL PV-10 led to regression of the injected lesion as well as the distant B16 melanoma lung metastases.

Splenocytes isolated from tumor bearing mice treated with IL PV-10 demonstrated enhanced tumor-specific IFN-gamma (interferon-gamma) production compared to splenocytes from saline-treated mice in both models. In addition, a significant increase in lysis of B16 cells by T-cells isolated after PV-10 treatment was observed. Transfer of T-cells isolated from tumor-bearing mice treated with IL PV-10 led to tumor regression in untreated mice bearing B16 melanoma.

The investigators concluded that these studies established that IL PV-10 therapy induced tumor-specific T-cell-mediated immunity, which supported the concept of combining IL PV-10 with immunotherapy for advanced malignancies. “Various injection therapies for melanoma have been examined over the past 40 years, but few have shown the promising results we are seeing with PV-10,” said senior author Dr. Shari Pilon-Thomas, assistant member of the immunology program at the Moffitt Cancer Center.

Related Links:
Provectus Pharmaceuticals, Inc.
Moffitt Cancer Center


comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Alternative splicing produces two protein isoforms (Photo courtesy of Wikimedia Commons).

Key Regulator of Cancer-Inducing Alternative Splicing Identified

Cancer researchers have identified the splicing factor RBM4 (RNA-binding protein 4) as a key determinant in processes that prevent tumor development and spread. RBM4 is known to be crucial to gene splicing... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Partnership Established to Decode Bowel Disease

23andMe (Mountain View, CA,USA), a personal genetics company, is collaborating with Pfizer, Inc. (New York, NY, USA), in which the companies will seek to enroll 10,000 people with inflammatory bowel disease (IBD) in a research project designed to explore the genetic factors associated with the onset, progression, severity,... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.